Association between chemokine receptor 5 delta32 polymorphism and susceptibility to cancer: a meta-analysis

References

• Guergnon J, Combadiere C. Role of chemokines polymorphisms in diseases. Immunol Lett 2012;145:15–22
   PubMed Web of Science ®Google Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217–42
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003;15:15–21
   PubMed Web of Science ®Google Scholar
• Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997;186:1373–81
   PubMed Web of Science ®Google Scholar
• Szczucinski A, Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 2007;115:137–46
   PubMed Web of Science ®Google Scholar
• Wedderburn LR, Robinson N, Patel A, et al. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum 2000;43:765–74
   PubMed Web of Science ®Google Scholar
• Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367–77
   PubMed Web of Science ®Google Scholar
• Benkirane M, Jin DY, Chun RF, et al. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997;272:30603–6
   PubMed Web of Science ®Google Scholar
• Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12:113–20
   PubMed Web of Science ®Google Scholar
• Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997;150:1723–34
   PubMed Web of Science ®Google Scholar
• Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003;198:1381–9
   PubMed Web of Science ®Google Scholar
• Kucukgergin C, Isman FK, Dasdemir S, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene 2012;511:7–11
   PubMed Web of Science ®Google Scholar
• Kucukgergin C, Isman FK, Cakmakoglu B, et al. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol 2012;31:1418–24
   PubMed Web of Science ®Google Scholar
• Bracci PM, Skibola CF, Conde L, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma 2010;51:497–506
   PubMed Web of Science ®Google Scholar
• Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology 2009;74:414–18
   PubMed Web of Science ®Google Scholar
• Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, et al. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med 2009;23:429–35
   PubMed Web of Science ®Google Scholar
• Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 2008;17:87–91
   PubMed Web of Science ®Google Scholar
• Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol 2008;67:516–22
   PubMed Web of Science ®Google Scholar
• Khademi B, Razmkhah M, Erfani N, et al. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 2008;14:45–50
   PubMed Web of Science ®Google Scholar
• Zheng B, Wiklund F, Gharizadeh B, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 2006;26:3669–74
   PubMed Web of Science ®Google Scholar
• Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726–31
   PubMed Web of Science ®Google Scholar
• Degerli N, Yilmaz E, Bardakci F. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 2005;38:248–52
   PubMed Web of Science ®Google Scholar
• Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004;41:e59
   PubMed Web of Science ®Google Scholar
• Zambra FMB, Biolchi V, Brum IS, Chies JAB. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Human Immunol 2013;74:1003–8
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157–61
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. The PTPN22 C1858T functional polymorphism and autoimmune diseases – a meta-analysis. Rheumatology (Oxford) 2007;46:49–56
   PubMed Web of Science ®Google Scholar
• Lee YH, Rho YH, Choi SJ, et al. PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 2007;27:827–33
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34
   PubMed Web of Science ®Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63
   PubMed Web of Science ®Google Scholar
• Gawron AJ, Fought AJ, Lissowska J, et al. Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand J Gastroenterol 2011;46:333–40
   PubMed Web of Science ®Google Scholar
• Guleria K, Sharma S, Manjari M, et al. p.R72P, PIN3 Ins16bp polymorphisms of TP53 and CCR5?32 in north Indian breast cancer patients. Asian Pac J Cancer Prev 2012;13:3305–11
   PubMed Web of Science ®Google Scholar
• Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 1996;7:1545–53
   PubMed Web of Science ®Google Scholar
• Wang G, Dong Z, Xu G, et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 1998;124:615–20
   PubMed Web of Science ®Google Scholar
• Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004;36:35–8
   PubMed Web of Science ®Google Scholar
• Wong MM, Fish EN. Chemokines: attractive mediators of the immune response. Semin Immunol 2003;15:5–14
   PubMed Web of Science ®Google Scholar
• Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol 2011;162:1453–69
   PubMed Web of Science ®Google Scholar
• Kohem CL, Brenol JC, Xavier RM, et al. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scand J Rheumatol 2007;36:359–64
   PubMed Web of Science ®Google Scholar
• Song GG, Kim JH, Lee YH. The chemokine receptor 5 delta32 polymorphism and type 1 diabetes, Behcet's disease, and asthma: a meta-analysis. Immunol Invest 2014;43:123–36
   PubMed Web of Science ®Google Scholar
• Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001;72:1199–205
   PubMed Web of Science ®Google Scholar